Prescription dermatology medicines for moderate-to-severe skin conditions.
Therapeutic Dermatology is Galderma's prescription medicines portfolio for moderate-to-severe skin conditions. It spans acne treatments Aklief, Differin, Epiduo and Epiduo Forte plus Benzac; rosacea therapies Mirvaso, Oracea and Soolantra; actinic keratosis photodynamic therapy Metvix; melasma treatment Tri-Luma; and onychomycosis therapy Loceryl.
The category includes Nemluvio (nemolizumab), the first IL-31 receptor alpha biologic approved for prurigo nodularis in August 2024 and atopic dermatitis in December 2024. Galderma states it holds leading positions in acne, rosacea and non-melanoma skin cancer treatments.
| Attribute | Therapeutic Dermatology | Dupixent | Opzelura | Rinvoq | |
|---|---|---|---|---|---|
| Provider | |  |  |  | |
| Founded | 1981 | 1973 | 1991 | 2013 | |
| Sells To | B2B, B2C | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Product Sales | Recurring | Recurring, Software | Recurring, Software | |
| Ownership | Public | Public | Public | Public |
Provider
Founded 1981
Sells To B2B, B2C
Pricing Model Product Sales
Ownership Public
Provider
Founded 1973
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 1991
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Dermatology portfolio of acne treatment, sunscreen, moisturizer, and topical corticosteroid products.
Biolab dermatology line of skin-care products spanning prevention and treatment.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
ABCL575 is an investigational half-life-extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis.
A half-life extended monoclonal antibody targeting kallikreins 5 and 7, in Phase 2 proof-of-concept trial for atopic dermatitis.
A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.
Dermatology portfolio of acne treatment, sunscreen, moisturizer, and topical corticosteroid products.
Biolab dermatology line of skin-care products spanning prevention and treatment.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
ABCL575 is an investigational half-life-extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis.
A half-life extended monoclonal antibody targeting kallikreins 5 and 7, in Phase 2 proof-of-concept trial for atopic dermatitis.
A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.